Exela Pharma Sciences Recalls Sodium Bicarbonate Injection Over Arsenic Impurity Concerns
Exela Pharma Sciences, LLC has initiated a Class II recall for its 4.2% Sodium Bicarbonate Injection due to out-of-specification arsenic impurities. This event, recall D-0620-2025, impacts nationwide distribution, necessitating immediate supply chain review for procurement directors. The Lenoir, NC facility is under scrutiny, demanding robust remediation and alternative sourcing strategies.
Exela Pharma Sciences Recalls Sodium Bicarbonate Injection Due to Arsenic Impurity Exceeding Specifications
Exela Pharma Sciences, LLC has initiated a voluntary, firm-initiated Class II recall, designated D-0620-2025, for its 4.2% Sodium Bicarbonate Injection, USP. This critical intravenous product, specifically the 5 mEq/10 mL (0.5 mEq/mL) single-dose vial, has been found to contain out-of-specification levels of arsenic impurities. The affected product, identified by Lot # 10004077 with an expiration date of February 28, 2026, was manufactured and distributed from Exela Pharma Sciences' facility in Lenoir, NC, and has reached markets nationwide across the USA. This recall, initiated on July 30, 2025, and classified by the FDA on September 5, 2025, underscores a significant quality control failure. For procurement directors and regulatory affairs heads, this means an immediate assessment of your inventory is paramount. Any stock of Exela Pharma Sciences' Sodium Bicarbonate Injection with NDC 51754-5012-1 (vial) or 51754-5012-4 (carton) from the specified lot must be identified and quarantined. The presence of arsenic, a known toxic element, even at trace levels exceeding specifications, poses potential patient safety risks, demanding swift action to remove affected product from circulation. This event highlights the critical importance of stringent raw material testing and in-process quality controls for all pharmaceutical manufacturers.
Exela Pharma Sciences' Lenoir, NC Facility Under Scrutiny Following Impurity Recall
The manufacturing facility located at 1245 Blowing Rock Blvd, Lenoir, NC 28645-3618, operated by Exela Pharma Sciences, LLC, is the origin point for the recalled 4.2% Sodium Bicarbonate Injection. This facility is now under heightened scrutiny from the FDA following the detection of arsenic impurities in a critical injectable product. The failure to meet impurity specifications at this site directly impacts the integrity and safety of a widely used medication. For supply chain VPs and business development executives, this event signals a potential vulnerability in the manufacturing processes at this specific location, which could lead to further regulatory actions or production interruptions. Ensuring the quality and safety of injectable drugs is non-negotiable, and a recall due to elemental impurities like arsenic points to fundamental issues in quality management systems. Companies sourcing any products from this Exela Pharma Sciences facility should initiate a thorough review of their supplier qualification documentation, focusing on the site's environmental controls, raw material sourcing, and analytical testing protocols. The incident necessitates a deeper dive into the facility's compliance history and current operational standards to mitigate future supply chain risks and ensure continuity of safe product supply.
Supply Chain Implications of Exela Pharma Sciences' Sodium Bicarbonate Recall
The nationwide distribution of Exela Pharma Sciences' 4.2% Sodium Bicarbonate Injection means that healthcare providers across the United States are directly impacted by this Class II recall. Sodium Bicarbonate Injection is a critical medication used for various conditions, including metabolic acidosis, making its availability essential. Procurement directors must immediately assess their current stock levels, identify any affected lot numbers, and initiate procedures for return or destruction as advised by Exela Pharma Sciences and the FDA. The disruption caused by this recall necessitates a rapid re-evaluation of current sourcing strategies for this vital drug. Business development executives should recognize that such recalls can erode market confidence and create opportunities for competitors with robust quality systems. The immediate challenge for regulatory affairs heads is to ensure compliance with recall procedures while simultaneously safeguarding patient access to alternative, safe supplies. This event underscores the fragility of single-source dependencies and the imperative for diversified supply chains, especially for essential medicines. Companies relying on Exela Pharma Sciences for other products should also consider this incident in their overall risk assessment of the supplier.
Identifying Alternative Suppliers for Intravenous Sodium Bicarbonate
Given the recall of Exela Pharma Sciences' 4.2% Sodium Bicarbonate Injection, procurement teams must urgently identify and qualify alternative suppliers to ensure uninterrupted access to this critical intravenous medication. While specific alternative suppliers are not provided in our knowledge graph, the strategic approach involves evaluating manufacturers with a proven track record of FDA compliance and robust quality management systems. Key considerations include assessing their manufacturing capacity, regulatory history, and the geographic diversity of their production sites to mitigate future supply chain vulnerabilities. This proactive approach is essential to prevent stockouts and maintain patient care standards. Regulatory affairs heads should prioritize due diligence on potential new suppliers, verifying their FDA inspection history, product quality data, and stability profiles for Sodium Bicarbonate. Qualification timelines for new pharmaceutical suppliers can be extensive, often spanning several months, making immediate action imperative. Supply chain VPs should establish clear contingency plans, including multi-sourcing strategies, to build resilience against similar unforeseen quality issues. This incident serves as a stark reminder that reliance on a single supplier, or a supplier with emerging quality concerns, introduces unacceptable risk into the pharmaceutical supply chain.
Assessing Exela Pharma Sciences' Regulatory Compliance Record
Our current intelligence indicates that specific prior regulatory actions or a detailed compliance history for Exela Pharma Sciences, LLC are not available in the provided knowledge graph. Therefore, this Class II recall (D-0620-2025) for out-of-specification arsenic impurities in their 4.2% Sodium Bicarbonate Injection represents a significant and publicly documented regulatory event for the company. For regulatory affairs heads, this absence of extensive prior public record means that this incident will likely be a primary data point for future FDA scrutiny and risk assessments. The FDA's classification of this as a Class II recall signifies a situation where the use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. While we cannot detail a pattern of compliance risk for Exela Pharma Sciences from the available data, the broader regulatory environment shows ongoing vigilance. Recent parallel events, such as Essential Wellness Pharma's progesterone injection recall for sterility issues or FDA hearings impacting Amgen's Tavneos, underscore the FDA's persistent focus on manufacturing quality and product safety across the pharmaceutical sector. This context means Exela Pharma Sciences' current recall will be viewed within an environment of heightened regulatory expectations, requiring a thorough and transparent remediation process to restore confidence.
Navigating Remediation and Future Regulatory Actions for Exela Pharma Sciences
The recall of Exela Pharma Sciences' Sodium Bicarbonate Injection is currently classified as 'Ongoing,' indicating that the firm is actively managing the recall process and the FDA is monitoring its progress. For Exela Pharma Sciences, this necessitates a comprehensive investigation into the root cause of the arsenic impurity, which could stem from raw materials, manufacturing processes, or environmental contamination. The company is required to implement robust Corrective and Preventive Actions (CAPA) to address these findings and prevent recurrence. This involves not only fixing the immediate problem but also demonstrating systemic improvements to their quality management system. For procurement directors and regulatory affairs heads, monitoring Exela Pharma Sciences' remediation timeline and the FDA's subsequent actions is crucial. The FDA will likely conduct follow-up inspections at the Lenoir, NC facility to verify the effectiveness of the CAPA plan. Failure to adequately address the identified deficiencies could lead to further regulatory enforcement, including a Warning Letter, product seizure, or even an Import Alert if the facility were to supply international markets. Business development executives should understand that a prolonged or ineffective remediation process could severely impact Exela Pharma Sciences' market standing and ability to secure future contracts, making transparent and effective resolution paramount for their long-term viability.